Madrigal Expands Rezdiffra Evidence With 12,000-Patient Study
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) will present new clinical and real-world research on its liver disease treatment Rezdiffra at a medical conference in Denver beginning November 5, …
Madrigal Expands Rezdiffra Evidence With 12,000-Patient Study Read More